4Q23 non-GAAP EPS—which excludes the cost of the announced earplug and PFAS settlements and related legal expenses —was $2.42, +11% YoY.
4Q23 sales were $8.0B, -0.8% YoY.
4Q23 organic sales growth (excluding FX, acquisitions, and divestitures) was -1.9% YoY.
3M issued 2024 non-GAAP EPS guidance—which excludes the cost of the announced earplug and PFAS settlements and related legal expenses—of $9.35-9.75, +1-6% YoY vs $9.24 in 2023.
2024 guidance for sales growth is 0.25-2.25%. 2024 guidance for organic sales growth is 0-2.0%.
3M’s healthcare spin-off, Solventum, is still slated to occur during 1H24; see #msg-173243340 for related info.